5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Amid Stoke Therapeutics’ (NASDAQ:STOK) impressive 31% surge over the past week and trading near its 52-week high at $18.21, Jonathan Allan, General Counsel at the ~$991 million market cap company, sold 13,712 shares of common stock on August 13, 2025, at a price of $15.0, for a total value of $205,680.
Following the transaction, Allan directly owns 19,631 shares, which includes 1,778 shares acquired through the company’s Employee Stock Purchase Plan.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024.
In other recent news, Stoke Therapeutics Inc reported its financial results for the second quarter of 2025, surpassing analyst expectations. The company posted a loss per share of $0.40, which was narrower than the anticipated loss of $0.50 per share. Additionally, Stoke Therapeutics achieved revenue of $13.8 million, exceeding the forecasted $9.39 million. These results highlight the company’s stronger-than-expected performance in the recent quarter. The announcement of these earnings figures was followed by a positive reaction in the stock market. While the stock price movement is not the focus here, it is important to note the company’s financial achievements. These developments are part of the recent updates that investors may find relevant for evaluating Stoke Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.